News

2015 ACR RA guidelines criticized on steroid, HBV screening, cancer history advice

Publish date: February 25, 2016

 

References

None of these authors reported funding sources or conflicts of interest.

Pages

Recommended Reading

ACR: Push back when insurance decisions force TNFi change
MDedge Rheumatology
Biologic treatment in pregnancy requires balancing risks
MDedge Rheumatology
Step therapy and biologics: An easier road ahead?
MDedge Rheumatology
Rituxan led Medicare part B drug spending in 2014
MDedge Rheumatology
Potential etanercept response biomarker identified
MDedge Rheumatology
Biosimilar infliximab gains FDA Advisory Committee endorsement
MDedge Rheumatology
Greater myocardial inflammation found in RA patients after heart attack
MDedge Rheumatology
Biosimilar program reshapes FDA’s objectivity
MDedge Rheumatology
Ultrasound could help identify patients suitable for biologic tapering
MDedge Rheumatology
Once-daily tofacitinib formulation gets FDA clearance for RA
MDedge Rheumatology